Pay in 4 interest-free payments of $6.43 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
Kim S, et al
Clinical trials used 2.4 mg as the primary endpoint dose, where participants lost an average of 14.9% of body weight over 68 weeks
Catalog item BPC-157 5mg Listed amount 5mg Material class Synthetic pentadecapeptide research material Permitted context Qualified laboratory research only Planning work with this material A defensible study plan should record the exact material identifier, source, lot, receipt condition, storage control, preparation method, and analytical acceptance criteria
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial
US$ 21.12
US$ 26.50
US$ 22.61
